Rapamycin

Rapamycin, also known as Sirolimus, is an FDA-approved drug primarily known for its immunosuppressant properties. However, research suggests it may also have potential as a longevity treatment. Studies, particularly in animal models, have shown that rapamycin can increase healthspan and reduce inflammation. Specifically, mouse studies have demonstrated substantial increases in healthspan, and reductions in inflammatory markers. Furthermore, human studies indicate that rapamycin can improve survival rates from acute infections.

While the potential benefits of rapamycin are promising, it's important to consider the current state of the evidence. A significant portion of the research is based on animal studies, and the effects observed in animals may not directly translate to humans. Human studies have shown mixed results, with some indicating increased pain as a potential side effect.

It's also crucial to note that there are currently no randomized controlled trials (RCTs) or meta-analyses specifically investigating rapamycin's impact on lifespan extension or overall longevity in humans. Therefore, while the existing evidence suggests potential benefits, further high-quality human research, including RCTs, is needed to fully understand rapamycin's efficacy and safety as a longevity treatment. The current evidence base is limited by the lack of robust human clinical trials.